Testing blood and tumor markers to guide lymphoma treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at “biomarkers” (measurable signs in your tumor and possibly blood) to understand your lymphoma’s genetic make-up. The goal is to see which markers may help doctors decide on treatment and timing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to take part in the study (no refusal of participation)
- You have been diagnosed with a lymphoma type such as diffuse large B-cell lymphoma or other specified lymphomas
- You are not currently on lymphoma treatment, or you only had steroids in the past 14 days (up to a total of 500 mg)
- Your care team expects you will need whole-body (systemic) treatment within 30 days of screening
- You have not had lymphoma treated only with surgery and/or local radiation for a limited area
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at “biomarkers,” or measurable signals in blood, in people with multiple myeloma who are being treated for the first time. It may help researchers understand the disease better and how it responds to treatment.
This trial looks at blood samples to measure substances that may reflect cancer (tumor markers). It may help doctors understand cancer better and improve future monitoring, as long as you can safely and regularly take part.
This trial studies a blood test that looks for circulating tumor markers in people with any type of invasive cancer (newly diagnosed or suspected). The goal is to see if markers in the blood can help monitor the cancer and guide treatment.
This study checks whether measuring a blood test called “circulating tumor DNA” (ctDNA) helps monitor childhood lymphoma during treatment. It’s meant to see if ctDNA tracking can provide useful information alongside standard exams.
This study looks for tumor “signatures” (including tiny RNA molecules, or miRNA) to predict outcomes in people with relapsed or resistant diffuse large B‑cell lymphoma (DLBCL). Your tissue samples help researchers see which patients may benefit from standard chemotherapy plus antibody treatment.
This study measures “circulating tumor markers,” meaning substances from cancer that can show up in blood, to better understand how cancer is doing after treatment. You may join if you recently received cancer care at a participating center and meet basic study and follow-up requirements.
Hear when a new Lymphomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.